ASCO 2017 | ‘It’s all about checkpoint inhibitors’ – Rob Jones on bladder cancer during ASCO 2017

Rob Jones, MD, University of Glasgow, UK gives us a neat round up of the important bladder cancer data being presented at ASCO 2017 as well as how physicians might use these data to inform their practice going forward. He discusses data from the pembrolizumab KEYNOTE-45 study and a study combining the PD1 checkpoint inhibitor with a novel IDO inhibitor.